@inproceedings{63d68eefed9a4ba1b3f0d4263c17528d,
title = "Ipilimumab in patients with melanoma brain metastases, a single-center experience in an expanded access program.",
abstract = "Background: patients (pts) diagnosed with melanoma brain metastases (MBM) have a poor prognosis with conventional treatment options. Ipilimumab (IPI) is a CTLA-4 blocking monoclonal antibody with established activity in patients (pts) with pretreated advanced melanoma. Methods: observational study on the clinical outcome of melanoma pts with a prior diagnosis of MBM among pts treated with IPI (3 mg/kg q3wks x4, allowing for retreatment after a PFS of >24 wks) in an expanded access program at a single center. Results: among the 50 pts who initiated IPI treatment between April 2010 and May 2011, 16 pts had been diagnosed with MBM. Only 1 pt had a solitary MBM, all other pts had > 3 MBM. Baseline characteristics for pts with- and without MBM: M/F 8/8 vs. 20/14; mAge 44- vs. 50y; BRAF V600-mut/wt 10/6 vs 19/15; stage IV-M1c/-a&b 16/0 vs 31/3; WHO-PS 0-1/2 9/7 vs 30/4; LDH >ULN 10/6 vs 23/11; CRP >ULN 10/6 vs 20/14; ALC",
keywords = "melanoma, brain metastases, ipilimumab, immunotherapy",
author = "{Du Four}, Stephanie and Sofie Wilgenhof and A. Seghers and Johnny Duerinck and Bart Neyns",
year = "2013",
month = may,
language = "English",
volume = "30",
number = "15",
pages = "19027",
booktitle = "Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition).",
note = "2012 ASCO Annual Meeting ; Conference date: 01-05-2012",
}